Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia

Figure 1

Risk assessment of ALL patients treated within several different trial treatment regimens correlated with patient outcome. Kaplan-Meier curves are shown for the 182 pediatric ALL patients assessed retrospectively in this study. Patients were treated within ALL BFM 2000, ALL-BFM 1995, ALL-BFM 1990, Interfant, EsPhALL, CoALL and CoALL/BFM. A-B. Patients with a standard risk (SR) ALL have a significant better EFS and OS than those with a medium (MR) or high risk (HR) ALL. C-D. There is no significant difference concerning EFS or OS between combined AC/AA genotype and CC genotype of the BCL2−938C > A polymorphism.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us